Breaking News, Financial News

Regeneron 4Q and FY20 Results

REGEN-COV antibody cocktail for COVID-19 received FDA EUA; Net sales of REGEN-COV were $146 million in the quarter and $186 million for the year.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Regeneron 4Q Revenues: $2.4 billion (+30%) 4Q Earnings: $1.1 billion (+5%) YTD Revenues: $8.5 billion (+30%) YTD Earnings: $3.5 billion (+66%) Comments: EYLEA U.S. sales increased 10% to $1.3 billion in the quarter. Full year EYLEA sales in the U.S. increased to $4.9 billion, up 7%. Dupixent global sales, which are recorded by Sanofi, increased 56% to $1.17 in the quarter. REGEN-COV antibody cocktail for COVID-19 received FDA Emergency Use Authorization. Regeneron signed an agreement with U...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters